Univariable analysis for PFS and OS
| . | . | PFS . | OS . | Reference . | ||
|---|---|---|---|---|---|---|
| Variable . | . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Age | Age ≥60 y | 1.247 (0.729-2.133) | .4206 | 1.327 (0.753-2.338) | .3282 | Age <60 y |
| Gender | Female | 0.983 (0.546-1.649) | .8527 | 0.919 (0.508-1.661) | .7798 | Male |
| KPS | KPS 70-80 | 1.366 (0.779-2.397) | .2765 | 1.421 (0.789-2.56) | .242 | KPS 90-100 |
| Stage | 3-4 | 0.957 (0.504-1.819) | .8938 | 0.786 (0.408-1.512) | .4705 | Stage 1-2 |
| LDH | High LDH | 1.105 (0.584-2.09) | .7585 | 1.179 (0.6-2.316) | .6331 | Normal LDH |
| IPI at transplant | IPI at SCT ≥2 | 1.432 (0.774-2.649) | .2528 | 1.093 (0.558-2.14) | .7963 | IPI at SCT <2 |
| LDH at transplant | High LDH | 2.08 (1.216-3.557) | .0075 | 1.709 (0.968-3.017) | .0646 | Normal LDH |
| CNS involvement site | Parenchymal | 0.495 (0.245-0.998) | .0493 | 0.529 (0.252-1.108) | .0915 | LMD |
| Leptomeningeal and parenchymal | 0.913 (0.392-2.131) | .8341 | 0.95 (0.401-2.252) | .9078 | ||
| CSF Only | 0.762 (0.263-2.208) | .6162 | 0.958 (0.326-2.816) | .9385 | ||
| Others* | 0.635 (0.293-1.378) | .2511 | 0.55 (0.231-1.306) | .1752 | ||
| Extent of disease prior to transplant | CNS and Systemic | 1.677 (0.813-3.458) | .1619 | 1.512 (0.724-3.156) | .2707 | Isolated CNS relapse |
| Systemic alone | 1.115 (0.302-4.122) | .8703 | 1.197 (0.323-4.429) | .7878 | ||
| Prior lines of therapy | >2 | 2.849 (1.663-4.882) | .0001 | 3.045 (1.713-5.411) | .0001 | Prior lines of therapy ≤2 |
| Time from diagnosis to transplant | ≤18 mo | 0.714 (0.418-1.218) | .2158 | 0.613 (0.347-1.084) | .0926 | >18 mo |
| Disease status at transplant | Not in remission | 4.883 (2.806-8.499) | <.0001 | 3.971 (2.215-7.118) | <.001 | CR/CRu |
| CNS-directed therapy | Cytarabine-based | 0.983 (0.385-2.515) | .9722 | 1.203 (0.413-3.505) | .7343 | Intrathecal chemotherapy alone |
| Methotrexate-based | 1.037 (0.418-2.572) | .9375 | 1.241 (0.437-3.529) | .6852 | ||
| Methotrexate/Cytarabine-based | 1.238 (0.512-2.994) | .6363 | 1.556 (0.567-4.270) | .3909 | ||
| Conditioning | Thiotepa-based | 1.495 (0.-2.83) | .2166 | 1.131 (0.5-2.317) | .7367 | BEAM |
| GBM-based | 1.508 (0.7-3.217) | .2876 | 1.411 (0.6-3.139) | .3983 | ||
| . | . | PFS . | OS . | Reference . | ||
|---|---|---|---|---|---|---|
| Variable . | . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Age | Age ≥60 y | 1.247 (0.729-2.133) | .4206 | 1.327 (0.753-2.338) | .3282 | Age <60 y |
| Gender | Female | 0.983 (0.546-1.649) | .8527 | 0.919 (0.508-1.661) | .7798 | Male |
| KPS | KPS 70-80 | 1.366 (0.779-2.397) | .2765 | 1.421 (0.789-2.56) | .242 | KPS 90-100 |
| Stage | 3-4 | 0.957 (0.504-1.819) | .8938 | 0.786 (0.408-1.512) | .4705 | Stage 1-2 |
| LDH | High LDH | 1.105 (0.584-2.09) | .7585 | 1.179 (0.6-2.316) | .6331 | Normal LDH |
| IPI at transplant | IPI at SCT ≥2 | 1.432 (0.774-2.649) | .2528 | 1.093 (0.558-2.14) | .7963 | IPI at SCT <2 |
| LDH at transplant | High LDH | 2.08 (1.216-3.557) | .0075 | 1.709 (0.968-3.017) | .0646 | Normal LDH |
| CNS involvement site | Parenchymal | 0.495 (0.245-0.998) | .0493 | 0.529 (0.252-1.108) | .0915 | LMD |
| Leptomeningeal and parenchymal | 0.913 (0.392-2.131) | .8341 | 0.95 (0.401-2.252) | .9078 | ||
| CSF Only | 0.762 (0.263-2.208) | .6162 | 0.958 (0.326-2.816) | .9385 | ||
| Others* | 0.635 (0.293-1.378) | .2511 | 0.55 (0.231-1.306) | .1752 | ||
| Extent of disease prior to transplant | CNS and Systemic | 1.677 (0.813-3.458) | .1619 | 1.512 (0.724-3.156) | .2707 | Isolated CNS relapse |
| Systemic alone | 1.115 (0.302-4.122) | .8703 | 1.197 (0.323-4.429) | .7878 | ||
| Prior lines of therapy | >2 | 2.849 (1.663-4.882) | .0001 | 3.045 (1.713-5.411) | .0001 | Prior lines of therapy ≤2 |
| Time from diagnosis to transplant | ≤18 mo | 0.714 (0.418-1.218) | .2158 | 0.613 (0.347-1.084) | .0926 | >18 mo |
| Disease status at transplant | Not in remission | 4.883 (2.806-8.499) | <.0001 | 3.971 (2.215-7.118) | <.001 | CR/CRu |
| CNS-directed therapy | Cytarabine-based | 0.983 (0.385-2.515) | .9722 | 1.203 (0.413-3.505) | .7343 | Intrathecal chemotherapy alone |
| Methotrexate-based | 1.037 (0.418-2.572) | .9375 | 1.241 (0.437-3.529) | .6852 | ||
| Methotrexate/Cytarabine-based | 1.238 (0.512-2.994) | .6363 | 1.556 (0.567-4.270) | .3909 | ||
| Conditioning | Thiotepa-based | 1.495 (0.-2.83) | .2166 | 1.131 (0.5-2.317) | .7367 | BEAM |
| GBM-based | 1.508 (0.7-3.217) | .2876 | 1.411 (0.6-3.139) | .3983 | ||
ARA-C, cytarabine; CRu, complete response uncertain; CSF, cerebrospinal fluid; GBM, gemcitabine, busulphan, melphalan; HR, hazard ratio; KPS, Karnofsky performance scale; LDH, lactate dehydrogenase.
Included patients with isolated neurolymphomatosis, intramedullary spinal dissemination, and others not otherwise classified such as epidural with nerve root or spine involvement.